---
title: "ACCENDRA HEALTH 2026: Revenue $613.23M, EPS ($1.16) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295426162.md"
description: "Accendra Health reported Q2 2026 net revenue of $613.23M, a 10.1% YoY decline due to the loss of major payor contracts removing ~$81M in revenue. Net loss narrowed significantly to ($89.07M) from ($869.06M), with diluted EPS improving to ($1.16) from ($11.3). Excluding contract impacts, Diabetes, Ostomy, and Urology segments showed growth. The company also sold its Products & Healthcare Services business and reduced SG&A through operational efficiencies."
datetime: "2026-08-10T15:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295426162.md)
  - [en](https://longbridge.com/en/news/295426162.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295426162.md)
generator: "portal-rs"
---

# ACCENDRA HEALTH 2026: Revenue $613.23M, EPS ($1.16) — 10-Q Summary

ACCENDRA HEALTH reported second-quarter 2026 results with net revenue of $613.23M and a net loss of ($89.07M), or diluted loss per share of ($1.16), versus prior-year quarter revenue of $681.92M and a net loss of ($869.06M) (diluted loss per share ($11.3)).

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$613.23M

$681.92M

(10.1%)

Net income²

($89.07M)

($869.06M)

89.8%

Diluted EPS³

($1.16)

($11.3)

89.7%

*¹ Reported as “Net revenue”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per common share”.*

**Business Highlights**

-   Revenue trends: Net revenue declined roughly 10% in Q2 and about 8.5% year-to-date, driven largely by the loss of a commercial payor contract that reduced capitation and related sales.
-   Channel shift & contract loss: Termination of major payor contracts completed in H1 2026 removed approximately $81M in Q2 and $123M year-to-date revenue, notably impacting sleep and home respiratory therapy.
-   Product mix momentum: Excluding payor termination impacts, Diabetes, Ostomy and Urology showed growth in Q2 of about $7.8M, $3.8M and $2.6M, respectively.
-   Operational actions: Completed sale of the Products & Healthcare Services business (retaining a 5% equity stake) and executed balance-sheet optimization to focus core operations and transition services.
-   Operational efficiency: SG&A was reduced versus the prior year through personnel and other savings; equipment sales in H1 generated meaningful proceeds tied to contract transitions.

Original SEC Filing: ACCENDRA HEALTH INC/VA/ \[ ACH \] - 10-Q - Aug. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ACH.US](https://longbridge.com/en/quote/ACH.US.md)

## Related News & Research

- [BIOVIC_B: 56% sales growth and strong Pharma Services momentum, with a SEK 29.2M rights issue to fund growth](https://longbridge.com/en/news/298480525.md)
- [Coherent director Lisa Neal-Graves sells 2,200 shares worth $590,524](https://longbridge.com/en/news/298072199.md)
- [HSBC Gradually Scales Back Transaction Services Business in Germany, Cutting More Than 300 Jobs](https://longbridge.com/en/news/298438432.md)
- [KURA: KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead](https://longbridge.com/en/news/298474937.md)
- [TJX Companies declares R$ 1.66 dividend per unit, payable Sept. 10](https://longbridge.com/en/news/298325734.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**